Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ)
CNY 12.4
(-0.08%)
CNY 12.4
(-0.08%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -36.5 Million | -54.48 Million | -46.01 Million | 18.51 Million | 48.41 Million | 74.45 Million |
| Net Income | -322.13 Million | -868.19 Thousand | 278.68 Million | -198.17 Million | 73.08 Million | -92.55 Million |
| Depreciation & Amortization | 70.63 Million | 74.86 Million | 65.9 Million | 59.68 Million | 57.99 Million | 59.24 Million |
| Deferred income taxes | 5.54 Million | 12.44 Million | -194.02 Thousand | -3.58 Million | -222.85 Thousand | 3.19 Million |
| Stock-based compensation | 15.42 Million | - | - | - | - | - |
| Change in working capital | 66.38 Million | 67.26 Million | 66.02 Million | 171.51 Million | 9.24 Million | -15.6 Million |
| Other non-cash items | 13.43 Million | -195.74 Million | -456.63 Million | -14.5 Million | -91.91 Million | 123.37 Million |
| Investing Cash Flow | 256.64 Million | -38.41 Million | -55.82 Million | -6.89 Million | -66.06 Million | -613.29 Million |
| Investments in PPE | -4.31 Million | -31.46 Million | -60.84 Million | -67.69 Million | -36.27 Million | -608.26 Million |
| Acquisitions | 4.77 Million | 24.45 Million | 16.35 Thousand | 233.03 Thousand | 352.1 Thousand | 606.43 Thousand |
| Investment purchases | - | -50 Million | -5.01 Million | -60.51 Million | -20 Million | -155.63 Million |
| Sales/Maturities of investments | 256.19 Million | 22 Million | 5 Million | 46.07 Million | 2.17 Million | 300 Million |
| Other Investing Activities | 260.96 Million | -3.4 Million | 5.01 Million | 75 Million | -12.31 Million | -150 Million |
| Financing Cash Flow | -211.14 Million | 47.89 Million | 5.49 Million | -788.45 Million | -463.57 Million | 268.17 Million |
| Debt repayment | -133.16 Million | -229 Million | -188 Million | -875.11 Million | -530 Million | -100.5 Million |
| Dividends payments | -10.27 Million | -8.04 Million | -6.7 Million | -55.34 Million | -60.39 Million | -75.53 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -67.7 Million | 284.93 Million | 200.19 Million | 142.01 Million | 126.81 Million | 444.2 Million |
| Accounts receivables | 69.75 Million | 46.78 Million | 75.08 Million | 106.22 Million | 49.46 Million | 118.45 Million |
| Accounts payables | 6.24 Million | 24.16 Million | -15.39 Million | 73.25 Million | -28.7 Million | -70.96 Million |
| Inventory | -15.16 Million | -16.13 Million | 6.53 Million | -4.37 Million | -11.29 Million | 17.66 Million |
| Other working capital | 15.49 Million | 12.44 Million | -194.02 Thousand | -3.58 Million | -222.85 Thousand | -33.27 Million |
| Cash at beginning of period | 142.79 Million | 187.79 Million | 284.15 Million | 1.06 Billion | 1.54 Billion | 1.81 Billion |
| Cash at end of period | 151.79 Million | 142.79 Million | 187.79 Million | 284.15 Million | 1.06 Billion | 1.54 Billion |
| Capital Expenditure | -4.31 Million | -31.46 Million | -60.84 Million | -67.69 Million | -36.27 Million | -608.26 Million |
| Effect of forex changes on cash | -453.92 | 4326.55 | -960.63 | 9817.97 | 823.29 | 3431.60 |
| Net cash flow / Change in cash | 9 Million | -45 Million | -96.35 Million | -776.82 Million | -481.22 Million | -270.66 Million |
| Free Cash Flow | -40.82 Million | -85.94 Million | -106.86 Million | -49.18 Million | 12.14 Million | -533.81 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.91 Million | -27.7 Million | -322.13 Million | -362.17 Million | 83.47 Million | -32.25 Million |
| Depreciation & Amortization | 10.92 Million | 10.92 Million | 70.63 Million | 70.63 Million | -38.92 Million | 20.02 Million |
| Deferred income taxes | - | - | 5.54 Million | - | 46.84 Million | -47.96 Million |
| Stock-based compensation | 4.44 Million | - | 15.42 Million | 15.42 Million | -2.46 Million | 2.46 Million |
| Change in working capital | -3.08 Million | - | 66.38 Million | 70.09 Million | -5.45 Million | 5.45 Million |
| Other non-cash items | 192.68 Million | 12.5 Million | 13.43 Million | 183.06 Million | 229.77 Million | 23.27 Million |
| Investing Cash Flow | 215.58 Million | 78.74 Million | 256.64 Million | 27.05 Million | 254.12 Million | 10.65 Million |
| Investments in PPE | 6108.55 | -122.92 Thousand | -4.31 Million | 24.91 Million | -411.01 Thousand | 8.52 Million |
| Acquisitions | 303.08 Thousand | 25.05 Million | 4.77 Million | 1.1 Million | 1.01 Million | 2.1 Million |
| Investment purchases | - | - | - | - | -1.01 Million | -2.1 Million |
| Sales/Maturities of investments | 215.28 Million | 53.82 Million | 256.19 Million | 1.03 Million | 253.52 Million | 28.31 Thousand |
| Other Investing Activities | 215.58 Million | 78.87 Million | 260.96 Million | 2.14 Million | 1.01 Million | 2.1 Million |
| Financing Cash Flow | -1.01 Million | -93.36 Thousand | -211.14 Million | -153.91 Million | -39.9 Million | -8.56 Million |
| Debt repayment | -944.74 Thousand | - | -133.16 Million | -84.88 Million | -39.8 Million | -15 Million |
| Dividends payments | -73.61 Thousand | -93.36 Thousand | -10.27 Million | -4.39 Million | -1.87 Million | -1.79 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -73.61 Thousand | -93.36 Thousand | -67.7 Million | -64.63 Million | 1.77 Million | 8.22 Million |
| Accounts receivables | -9.48 Million | - | 69.75 Million | 69.75 Million | -13.5 Million | 13.5 Million |
| Accounts payables | - | - | 6.24 Million | - | - | - |
| Inventory | 6.39 Million | - | -15.16 Million | -15.16 Million | 8.05 Million | -8.05 Million |
| Other working capital | - | - | 15.49 Million | 15.49 Million | - | - |
| Cash at beginning of period | 215.24 Million | 151.79 Million | 142.79 Million | 317.04 Million | 43.1 Million | 70.05 Million |
| Cash at end of period | 394.38 Million | 215.24 Million | 151.79 Million | 151.79 Million | 317.04 Million | 43.1 Million |
| Capital Expenditure | 6108.55 | -122.92 Thousand | -4.31 Million | 24.91 Million | -411.01 Thousand | 8.52 Million |
| Effect of forex changes on cash | 142.80 | 131.63 | -453.92 | -453.92 | -253.52 Million | -28.31 Thousand |
| Net cash flow / Change in cash | 179.13 Million | 63.45 Million | 9 Million | -165.24 Million | 273.93 Million | -26.95 Million |
| Free Cash Flow | 179.85 Million | -15.32 Million | -40.82 Million | -13.46 Million | 312.83 Million | -20.48 Million |
ORES
QCRH
3490
MLP
TOST
SHG